Skip to main content

Table 3 Phe-MR analyses for causal associations of HDL-C and acetate with the risk of multiple non-breast cancer diseases

From: Association between human blood metabolome and the risk of breast cancer

PheCode

Outcome

Disease chapter

IVW

Weighted median

MR-RAPS

MR-Egger Intercept

OR (95% CI)

P value

OR (95% CI)

P value

OR (95% CI)

P value

P value

HDL-C

411.4

Coronary atherosclerosis

Circulatory system

1.30 (1.25–1.36)

4.13 × 10–11

1.23 (1.18–1.29)

3.96 × 10–6

1.32 (1.29–1.35)

2.45 × 10–33

0.07

442.11

Abdominal aortic aneurysm

Circulatory system

1.53 (1.40–1.67)

1.04 × 10–9

1.49 (1.29–1.73)

7.56 × 10–6

1.54 (1.42–1.67)

1.01 × 10–9

0.52

444

Arterial embolism and thrombosis

Circulatory system

1.91 (1.72–2.12)

7.01 × 10–10

2.24 (1.86–2.69)

1.12 × 10–5

1.92 (1.74–2.12)

2.32 × 10–11

0.71

1001

Foreign body injury

Injuries and poisonings

1.72 (1.58–1.87)

1.79 × 10–10

1.94 (1.65–2.27)

3.01 × 10–5

1.73 (1.59–1.88)

2.10 × 10–10

0.19

Acetate

318

Tobacco use disorder

Mental disorders

2.87 (2.39–3.45)

6.87 × 10–9

3.11 (2.37–4.07)

2.84 × 10–5

2.95 (2.44–3.56)

1.21 × 10–8

0.92

  1. Odds ratios (ORs) with their 95% confidence intervals (CIs) represent the effect estimates on the risk of multiple non-breast cancer diseases of per 10% reduction in risk for breast cancer by targeting HDL-C and acetate, respectively
  2. Significant threshold in stage 2 was set at set at P < 0.05/1358 = 3.68 × 10–5, which was corrected for multiple comparisons using the Bonferroni method (0.05/1358 [2 identified breast cancer metabolites in stage 1 × 679 diseases])
  3. IVW inverse-variance weighted, MR-RAPS Mendelian randomization robust adjusted profile score, Phe-MR phenome-wide Mendelian randomization, SNPs single nucleotide polymorphisms